DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide studied for its roles in sleep regulation, stress response modulation, and neuroendocrine signaling. It was first isolated from rabbit cerebral venous blood in 1977 and has since been studied in various preclinical and clinical contexts. This review summarizes the adverse effects observed in available research.
Research Use Only: This information is for educational and research purposes only. DSIP is not FDA-approved for human use. Consult a qualified healthcare professional before any use.
DSIP modulates sleep architecture by influencing delta wave activity and interacting with multiple neurotransmitter systems including serotonin, dopamine, and GABA pathways. It also modulates the hypothalamic-pituitary-adrenal (HPA) axis, which may contribute to its stress-reducing effects.
Drowsiness is the most commonly reported effect of DSIP, consistent with its sleep-promoting mechanism of action. This is expected given its primary research application.
Mild redness, swelling, or discomfort at the injection site have been reported in research subjects receiving subcutaneous administration.
Mild dizziness has been reported in some research subjects, particularly at higher doses or when administered rapidly.
Mild headaches have been reported in a subset of research subjects.
Mild nausea has been reported at higher doses in some research contexts.
While DSIP promotes sleep, some subjects have reported changes in dream intensity or sleep quality, particularly during initial use.
DSIP has a long research history dating to the 1970s and has demonstrated a generally favorable safety profile in available studies. It is not FDA-approved for human use and should only be used in legitimate research settings. Its effects on the HPA axis warrant caution in subjects with endocrine disorders.
No evidence of physical dependence has been reported in DSIP research. Unlike benzodiazepines and other sleep medications, DSIP does not appear to cause tolerance or withdrawal effects based on available studies.
DSIP has demonstrated a generally favorable safety profile in available research. It is not FDA-approved for human use and should only be used in legitimate research settings.
DSIP modulates the HPA axis and may influence cortisol and other stress hormones. Research subjects with endocrine disorders should be monitored carefully.
Drowsiness is an expected effect of DSIP given its sleep-promoting mechanism. Excessive sedation has not been commonly reported in research at standard doses.
Purgo Labs provides research-grade DSIP with third-party HPLC and mass spectrometry verification from accredited US laboratories. Every batch ships with a full Certificate of Analysis.
Shop DSIP at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.